Lumera Receives Purchase Order from Harvard Medical School for a ProteomicProcessor Biosensor

BOTHELL, Wash.--(BUSINESS WIRE)--May 4, 2006--Lumera Corporation (NASDAQ:LMRA), an emerging leader in the field of nanotechnology, announced today that it had received a purchase order from Harvard Medical School (HMS) for its beta ProteomicProcessor(TM) Biosensor instrument.

"To have an organization of Harvard Medical School's standing purchase one of our beta instruments is extremely gratifying," said Dr. Tim Londergan, Director of Lumera's Bioscience Business Unit. "We look forward to demonstrating our instrument's capability with Dr. LaBaer's cancer biomarker platform and believe that data from this collaboration will enhance our value proposition with pharmaceutical customers."

“We look forward to demonstrating our instrument's capability with Dr. LaBaer's cancer biomarker platform and believe that data from this collaboration will enhance our value proposition with pharmaceutical customers.”

As previously announced, Lumera's strategy in this arena is to place five beta units with highly respected, world renowned research organizations to demonstrate and establish new applications, which take advantage of the instrument's unprecedented throughput. This purchase order from HMS is the second placement of the biosensor.

About Lumera

Lumera is a leader in the emerging field of nanotechnology. The company designs proprietary molecular structures and polymer compounds for the bioscience and communications/computing industries, both of which represent large market opportunities. The company also has developed proprietary processes for fabricating such devices. For more information, please visit www.lumera.com.

Certain statements contained in this release are forward-looking statements that involve a number of risks and uncertainties. Factors that could cause actual results to differ materially from those projected in the company's forward-looking statements include the following: market acceptance of our technologies and products; our ability to obtain financing; our financial and technical resources relative to those of our competitors; our ability to keep up with rapid technological change; government regulation of our technologies; our ability to enforce our intellectual property rights and protect our proprietary technologies; the ability to obtain additional contract awards and to develop partnership opportunities; the timing of commercial product launches; the ability to achieve key technical milestones in key products; and other risk factors identified from time to time in the company's SEC reports, including its Annual Report on Form 10-K, and its Quarterly Reports on Form 10-Q.